Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stromal cells (MSCs) developed by the University of Liege (University Hospital CHU of Liège) are an investigational cell-based therapy for the treatment of refractory Crohn's disease. These multipotent adult stem cells are isolated from bone marrow and expanded in vitro at the Laboratory of Cell and Gene Therapy. The therapy is administered via local injection into intestinal or perianal lesions, including strictures. MSCs exert their therapeutic effect through immunomodulatory, anti-inflammatory, and anti-fibrotic properties, aiming to promote tissue healing and mucosal recovery in patients who have failed conventional treatments. The treatment is currently being evaluated in Phase 1/2 clinical trials to assess safety and efficacy in healing refractory lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mesenchymal stromal cells (University of Liege).